公开(公告)号：US09198964B2

公开(公告)日：2015-12-01

申请号：US13881423

申请日：2011-10-27

申请人： Beth-Ann Griswold Coller ,  Vidya B. Pai ,  D. Elliot Parks ,  Michele Yelmene ,  Andrew J. Bett ,  Timothy Martyak

发明人： Beth-Ann Griswold Coller ,  Vidya B. Pai ,  D. Elliot Parks ,  Michele Yelmene ,  Andrew J. Bett ,  Timothy Martyak

IPC分类号： A61K39/12 ,  A61K39/00

CPC分类号： A61K39/12 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55577 ,  A61K2039/57 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/24134 ,  C12N2770/24171 ,  Y02A50/386

摘要： The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.

摘要翻译： 本发明提供登革热病毒疫苗和用于给予受试者的免疫原性组合物。 本发明的疫苗组合物包含重组产生的截短的登革热病毒包膜糖蛋白的单体和/或二聚体形式，当与佐剂和药学上可接受的载体一起配制时，诱导平衡的四价免疫应答。 在本文所述组合物的优选实施方案中，DEN4蛋白组分是DEN4的二聚体形式。 该组合物被设计为可接受用于一般群体，包括免疫抑制，免疫受损和免疫衰老个体。 本文还提供了通过将本文所述的组合物给予患者来诱导人类患者群体中的保护性免疫应答的方法。

公开(公告)号：US20130216575A1

公开(公告)日：2013-08-22

申请号：US13881423

申请日：2011-10-27

申请人： Beth-Ann Griswold Coller ,  Vidya B. Pai ,  D. Elliot Parks ,  Michele Yelmene ,  Andrew J. Bett ,  Timothy Martyak

发明人： Beth-Ann Griswold Coller ,  Vidya B. Pai ,  D. Elliot Parks ,  Michele Yelmene ,  Andrew J. Bett ,  Timothy Martyak

IPC分类号： A61K39/12

CPC分类号： A61K39/12 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55577 ,  A61K2039/57 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/24134 ,  C12N2770/24171 ,  Y02A50/386

摘要： The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.

摘要翻译： 本发明提供登革热病毒疫苗和用于给予受试者的免疫原性组合物。 本发明的疫苗组合物包含重组产生的截短的登革热病毒包膜糖蛋白的单体和/或二聚体形式，当与佐剂和药学上可接受的载体一起配制时，诱导平衡的四价免疫应答。 在本文所述组合物的优选实施方案中，DEN4蛋白组分是DEN4的二聚体形式。 该组合物被设计为可接受用于一般群体，包括免疫抑制，免疫受损和免疫衰老个体。 本文还提供了通过将本文所述的组合物给予患者来诱导人类患者群体中的保护性免疫应答的方法。